ClinicalTrials.gg
CompletedNCT01485614Updated Sep 23, 2022Results posted

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

A Phase 3 interventional study of Sitagliptin and Metformin in Diabetes Mellitus and Type 2 Diabetes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-09-23.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
72nd of 197
200 · median 102
Started
2012
with 15 others
Phase 3
74 of 198
none open now
Registered
111th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 72nd largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 74 in phase 3, and was the 111th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety of the addition of sitagliptin, and its effect on hemoglobin A1c (A1C) in pediatric participants 10-17 years of age with type 2 diabetes mellitus (T2DM) with inadequate glycemic control. The primary hypothesis for this study is that sitagliptin reduces A1C more than placebo after 20 weeks of treatment.

Read the detailed description

This trial is of approximately 56 weeks in duration, including a screening period of up to 1 week, a 1-week single-blind placebo run-in period, a 20-week placebo-controlled, double blind treatment period [Phase A] and a 34-week double-blind active controlled treatment period [Phase B] during which participants randomized to the placebo arm who have not initiated glycemic rescue therapy with metformin during Phase A will receive metformin (in a blinded manner). A telephone contact will be performed 14 days after the last dose of study medication to assess for any serious adverse events (SAEs).

Participants enrolled in the metformin and placebo/sitagliptin arms prior to implementation of Protocol Amendment 05 completed the study on their original treatment assignments.

EUPASS4468 is a follow-up, non-interventional, observational assessment of safety of participants who participated in the MK-0431-083 study for up to 5 years.

03

Conditions studied

  • Diabetes Mellitus
  • Type 2 Diabetes

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 200 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Type 2 Diabetes Mellitus (T2DM)
  • Has not received treatment with an antihyperglycemic agent (AHA) for ≥12 weeks prior to the Screening Visit/Visit 1, or is on a stable dose of insulin (without any other AHA) for at least 12 weeks prior to the Screening Visit/Visit 1. At screening, participants on insulin doses that are not stable can have their insulin doses adjusted and be eligible to participate after their dose remains stable for ≥12 weeks, if they meet all other eligibility criteria. In India, only participants on stable doses of insulin will be eligible.
  • An of ≥6.5% and ≤10.0% (For participants on insulin: an A1C ≥7.0% and ≤10.0%).

Exclusion Criteria:

  • History of type 1 diabetes mellitus, diabetes mellitus or has a positive antibody screen for anti-GAD (Glutamic Acid Decarboxylase) or (Islet cell autoantigen) ICA-512.
  • Known monogenic diabetes, secondary diabetes, or a genetic syndrome or disorder known to affect glucose tolerance other than diabetes.
  • Symptomatic hyperglycemia and/or moderate to large ketonuria and/or positive test for ketonemia requiring immediate initiation of antihyperglycemic therapy.
  • Previously taken a DPP-4 (Dipeptidyl peptidase-4) inhibitor (such as sitagliptin, vildagliptin, alogliptin, or saxagliptin) or GLP-1 (Glucagon-like peptide-1) receptor agonist (such as exenatide or liraglutide).
  • or (according to the product circular in the country of the site) to metformin.
  • Chronic treatment with a medication known to cause weight gain within 30 days of study start or weight loss or increased blood glucose within 8 weeks of study start or treated with an anti-psychotic within the past 12 weeks.
  • On a weight loss program and not in the maintenance phase or have undergone bariatric surgery within 12 months prior to study start.
  • On or likely to require treatment with ≥14 consecutive days or repeated courses of pharmacologic doses of .
  • Undergone a surgical procedure within the prior 4 weeks or has major surgery planned during the study.
  • History of congenital heart disease or cardiovascular disease other than hypertension.
  • Medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active or C, primary biliary cirrhosis, or symptomatic gallbladder disease.
  • Active nephropathy (i.e., nephrotic syndrome or glomerulonephritis).
  • Chronic myopathy, mitochondrial disorder, or a progressive neurological or neuromuscular disorder (e.g., polymyositis, or multiple sclerosis).
  • (HIV) as assessed by medical history.
  • hematological disorder (such as aplastic anemia, thrombocytopenia, myeloproliferative or myelodysplastic syndrome).
  • Under treatment for hyperthyroidism.
  • Exhibits abnormal growth patterns or is being treated with growth hormone.
  • History of or clinically important hematologic disorder.
  • History of idiopathic acute pancreatitis or chronic pancreatitis.
  • Known history of recreational or illicit drug use, or of alcohol abuse or dependence (within the past year).
  • Donated blood products or has had phlebotomy of >10% of estimated total blood volume within 8 weeks of signing , or intends to donate blood products or receive blood products within the projected duration of the study.
  • Pregnant, has a positive urine pregnancy test at Screening Visit/Visit 1, is expecting to conceive within the projected duration of the study, or is breast-feeding.
  • Exclusionary laboratory values.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.

    Drug: Sitagliptin · Drug: Placebo to metformin · Drug: Glycemic Rescue 1 · Biological: Glycemic Rescue 2

  • Placebo comparator
    Placebo/Metformin

    Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.

    Drug: Metformin · Drug: Placebo to sitagliptin · Drug: Placebo to metformin · Drug: Glycemic Rescue 1 · Biological: Glycemic Rescue 2

  • Active comparator
    Metformin

    Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.

    Drug: Metformin

  • Placebo comparator
    Placebo/Sitagliptin

    Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.

    Drug: Sitagliptin · Drug: Placebo to sitagliptin · Drug: Placebo to metformin

Interventions

  • Sitagliptin 100 mg tablet administered orally once daily

    Also known as: Januvia®, Tesavel®, Xelevia®, Ristaben®, Glactiv®

  • Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily

    Also known as: Glucophage®, Metgluco®, Glycoran®

  • DrugPlacebo to sitagliptin

    Matching placebo to sitagliptin 100 mg tablet administered orally once daily

  • DrugPlacebo to metformin

    Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily

  • DrugGlycemic Rescue 1

    Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.

  • BiologicalGlycemic Rescue 2

    Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (A1C) at Week 20

    Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C.

    Time frame: Baseline and Week 20

  2. Baseline Glycated Hemoglobin (A1C) for the Placebo (Pooled) Arm

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.

    Time frame: Baseline

  3. Change From Baseline In A1C at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))

    Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C from a longitudinal data analysis (LDA) model. The placebo arm in this comparison is a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The Statistical Analysis Plan (SAP) did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

    Time frame: Baseline and Week 20

  4. Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56

    The number of participants experiencing ≥1 adverse event during Weeks 0-56 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to Week 56

  5. Percentage of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)

    The number of participants experiencing ≥1 adverse event during Weeks 0-56 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

    Time frame: Up to Week 56

  6. Number of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54

    The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to Week 54

  7. Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)

    The percentage of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

    Time frame: Up to Week 54

Secondary outcomes

  1. Change From Baseline in A1C at Week 54

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. This change from baseline reflects the Week 54 A1C minus the Week 0 A1C.

    Time frame: Baseline and Week 54

  2. Percentage of Participants With A1C at Goal (<7.0%) at Week 20

    The percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).

    Time frame: Week 20

  3. Percentage of Participants With A1C at Goal (<7.0%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))

    The percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

    Time frame: Week 20

  4. Percentage of Participants With A1C at Goal (<6.5%) at Week 20

    The percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).

    Time frame: Week 20

  5. Percentage of Participants With A1C at Goal (<6.5%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))

    The percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

    Time frame: Week 20

  6. Percentage of Participants With A1C at Goal (<7.0%) at Week 54

    The percentage of participants with A1C at goal (\<7.0%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).

    Time frame: Week 54

  7. Percentage of Participants With A1C at Goal (<6.5%) at Week 54

    The percentage of participants with A1C at goal (\<6.5%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).

    Time frame: Week 54

  8. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20

    Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline.

    Time frame: Baseline and Week 20

  9. Baseline Fasting Plasma Glucose (FPG) for the Placebo (Pooled) Arm

    Blood glucose was measured on a fasting basis. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.

    Time frame: Baseline

  10. Change From Baseline in FPG at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))

    Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline and was estimated from a longitudinal data analysis model. The current outcome measure focused on results from participants randomized to sitagliptin or placebo. The Week 20 treatment comparison of Sitagliptin vs Placebo included all participants treated with Sitagliptin or Placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

    Time frame: Baseline and Week 20

  11. Change From Baseline in FPG at Week 54

    Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 54 minus FPG at baseline.

    Time frame: Baseline and Week 54

  12. Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 20

    PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour PMG minus the Week 0 2-hour PMG.

    Time frame: Baseline and Week 20

  13. Change From Baseline in 2-hour PMG at Week 54

    PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour PMG minus the Week 0 2-hour PMG.

    Time frame: Baseline and Week 54

  14. Change From Baseline in 2-hour Incremental PMG at Week 20

    2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.

    Time frame: Baseline and Week 20

  15. Change From Baseline in 2-Hour Incremental PMG at Week 54

    2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.

    Time frame: Baseline and Week 54

  16. Change From Baseline in Insulin at Week 20 for Participants Not on Background Insulin

    This change from baseline reflects the Week 20 insulin minus the Week 0 insulin.

    Time frame: Baseline and Week 20

  17. Change From Baseline in Insulin at Week 54 For Participants Not on Background Insulin

    This change from baseline reflects the Week 54 insulin minus the Week 0 insulin.

    Time frame: Baseline and Week 54

  18. Change From Baseline in Proinsulin at Week 20 For Participants Not on Background Insulin

    This change from baseline reflects the Week 20 proinsulin minus the Week 0 proinsulin.

    Time frame: Baseline and Week 20

  19. Change From Baseline in Proinsulin at Week 54 For Participants Not on Background Insulin

    This change from baseline reflects the Week 54 proinsulin minus the Week 0 proinsulin.

    Time frame: Baseline and Week 54

  20. Change From Baseline in Proinsulin/Insulin Ratio at Week 20 for Participants Not on Background Insulin

    Change from baseline was the Week 20 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.

    Time frame: Baseline and Week 20

  21. Change From Baseline in Proinsulin/Insulin Ratio at Week 54 For Participants Not on Background Insulin

    The change from baseline was Week 54 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.

    Time frame: Baseline and Week 54

  22. Change From Baseline in Homeostatic Model Assessment of β-cell Function (HOMA-β) at Week 20 For Participants Not on Background Insulin

    HOMA-β = 20 × fasting insulin (in mcIU/mL) ÷ {\[FPG (in mg/dL)/18\] - 3.5}. The change from baseline was Week 20 HOMA-β minus the Week 0 HOMA-β.

    Time frame: Baseline and Week 20

  23. Change From Baseline in HOMA-β at Week 54 For Participants Not on Background Insulin

    HOMA-β = 20 × fasting insulin (in mcIU/mL) ÷ {\[FPG (in mg/dL)/18\] - 3.5}. This change from baseline was Week 54 HOMA-β minus the Week 0 HOMA-β.

    Time frame: Baseline and Week 54

  24. Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 20 For Participants Not on Background Insulin

    HOMA-IR = fasting insulin (in mcIU/mL) × FPG (in mg/dL) / (22.5×18). This change from baseline was Week 20 HOMA-IR minus the Week 0 HOMA-IR.

    Time frame: Baseline and Week 20

  25. Change From Baseline in HOMA-IR at Week 54 For Participants Not on Background Insulin

    HOMA-IR = fasting insulin (in mcIU/mL) × FPG (in mg/dL) / (22.5×18). This change from baseline was Week 54 HOMA-IR minus the Week 0 HOMA-IR.

    Time frame: Baseline and Week 54

  26. Change From Baseline in Glucose 3-Hour Total Area Under the Curve (AUC) at Week 20

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.

    Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  27. Change From Baseline in Insulin 3-hour AUC at Week 20

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.

    Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  28. Change From Baseline in C-peptide 3-Hour AUC at Week 20

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.

    Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  29. Change From Baseline in Insulin 3-Hour AUC/ Glucose 3-Hour AUC Ratio at Week 20

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin total AUC/glucose total AUC ratio minus the Week 0 insulin total AUC/glucose total AUC ratio.

    Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  30. Change From Baseline in Glucose Excursion 3-Hour AUC at Week 20

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.

    Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  31. Change From Baseline in Insulin Excursion 3-Hour AUC at Week 20

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.

    Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  32. Change From Baseline in C-peptide Excursion 3-Hour AUC at Week 20

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.

    Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  33. Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 20

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.

    Time frame: Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  34. Change From Baseline in Glucose 3-Hour AUC at Week 54

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.

    Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  35. Change From Baseline in Insulin 3-Hour AUC at Week 54

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.

    Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  36. Change From Baseline in C-peptide 3-Hour AUC at Week 54

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.

    Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  37. Change From Baseline in Insulin 3-Hour AUC/Glucose 3-Hour AUC Ratio at Week 54

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC/glucose 3-hour AUC ratio minus the Week 0 insulin 3-hour AUC/glucose 3-hour AUC ratio.

    Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  38. Change From Baseline in Glucose Excursion 3-Hour AUC at Week 54

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.

    Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  39. Change From Baseline in Insulin Excursion 3-Hour AUC at Week 54

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.

    Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  40. Change From Baseline in C-Peptide Excursion 3-Hour AUC at Week 54

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.

    Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  41. Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 54

    AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.

    Time frame: Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)

  42. Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20

    The percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.

    Time frame: Up to Week 20

  43. Percentage of Participants Initiating Glycemic Rescue Therapy by Week 54

    The percentage of participants who initiated glycemic rescue therapy prior to Week 54 was reported.

    Time frame: Up to Week 54

  44. Change From Baseline in Body Mass Index (BMI) at Week 20

    This change from baseline was Week 20 BMI minus the Week 0 BMI.

    Time frame: Baseline and Week 20

  45. Change From Baseline in BMI at Week 54

    This change from baseline was Week 54 BMI minus the Week 0 BMI.

    Time frame: Baseline and Week 54

  46. Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 20

    The percent change from baseline in CD26 = (\[CD26 value at Week 20\] - \[baseline CD26 value\]) ÷ baseline CD26 value × 100.

    Time frame: Baseline and Week 20

  47. Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 54

    The percent change from baseline in CD26 = (\[CD26 value at Week 54\] - \[baseline CD26 value\]) ÷ baseline CD26 value × 100.

    Time frame: Baseline and Week 54

  48. Change From Baseline in Calcitonin at Week 20 - Females

    Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.

    Time frame: Baseline and Week 20

  49. Change From Baseline in Calcitonin at Week 54 - Females

    Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.

    Time frame: Baseline and Week 54

  50. Change From Baseline in Calcitonin at Week 20 - Males

    Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.

    Time frame: Baseline and Week 20

  51. Change From Baseline in Calcitonin at Week 54 - Males

    Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.

    Time frame: Baseline and Week 54

  52. Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Bone Collagen [u-NTx]/Creatinine Ratio at Week 20 - Females

    Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents

    Time frame: Baseline and Week 20

  53. Change From Baseline u-NTx/Creatinine Ratio at Week 20 - Males

    Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents

    Time frame: Baseline and Week 20

  54. Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Females

    Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. Bone Collagen Equivalents

    Time frame: Baseline and Week 54

  55. Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Males

    Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. All participants in the Metformin arm were missing baseline or Week 54 measurements. BCE = Bone Collagen Equivalents

    Time frame: Baseline and Week 54

  56. Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Females

    Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.

    Time frame: Baseline and Week 20

  57. Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Females

    Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.

    Time frame: Baseline and Week 54

  58. Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Males

    Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.

    Time frame: Baseline and Week 20

  59. Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Males

    Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.

    Time frame: Baseline and Week 54

  60. Percent Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) at Week 20 - Females

    IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 20\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.

    Time frame: Baseline and Week 20

  61. Percent Change From Baseline in IGF-1 at Week 54 - Females

    IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 54\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.

    Time frame: Baseline and Week 54

  62. Percent Change From Baseline in IGF-1 at Week 20 - Males

    IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 20\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.

    Time frame: Baseline and Week 20

  63. Percent Change From Baseline in IGF-1 at Week 54 - Males

    IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 54\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.

    Time frame: Baseline and Week 54

  64. Percent Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) at Week 20 - Females

    IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 20\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.

    Time frame: Baseline and Week 20

  65. Percent Change From Baseline in IGF-BP3 at Week 54 - Females

    IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 54\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.

    Time frame: Baseline and Week 54

  66. Percent Change From Baseline in IGF-BP3 at Week 20 - Males

    IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 20\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.

    Time frame: Baseline and Week 20

  67. Percent Change From Baseline in IGF-BP3 at Week 54 - Males

    IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 54\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.

    Time frame: Baseline and Week 54

  68. Growth Velocity at Week 20 - Females

    Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).

    Time frame: Week 20

  69. Growth Velocity at Week 54 - Females

    Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).

    Time frame: Week 54

  70. Growth Velocity at Week 20 - Males

    Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).

    Time frame: Week 20

  71. Growth Velocity at Week 54 - Males

    Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).

    Time frame: Week 54

  72. Skeletal Maturation at Week 20 - Females

    Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from an X-ray of left hand and wrist.

    Time frame: Week 20

  73. Skeletal Maturation at Week 54 - Females

    Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Placebo/Sitagliptin arm were missing baseline or Week 54 measurements.

    Time frame: Week 54

  74. Skeletal Maturation at Week 20 - Males

    Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist.

    Time frame: Week 20

  75. Skeletal Maturation at Week 54 - Males

    Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Metformin and Placebo/Sitagliptin arms were missing baseline or Week 54 measurements.

    Time frame: Week 54

  76. Change From Baseline in Tanner Staging for Genitalia at Week 20 - Males

    Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 20 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia.

    Time frame: Baseline and Week 20

  77. Change From Baseline in Tanner Staging for Genitalia at Week 54 - Males

    Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 54 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia. All participants in the Metformin arm were missing baseline or Week 54 measurements.

    Time frame: Baseline and Week 54

  78. Change From Baseline in Tanner Staging for Breasts at Week 20 - Females

    Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 20 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.

    Time frame: Baseline and Week 20

  79. Change From Baseline in Tanner Staging for Breasts at Week 54 - Females

    Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 54 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.

    Time frame: Baseline and Week 54

  80. Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Females

    Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.

    Time frame: Baseline and Week 20

  81. Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Females

    Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.

    Time frame: Baseline and Week 54

  82. Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Males

    Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.

    Time frame: Baseline and Week 20

  83. Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Males

    Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.

    Time frame: Baseline and Week 54

  84. Participants With Worsening in Dental Status at Week 20

    Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 20 dental assessments versus baseline dental assessments.

    Time frame: Week 20

  85. Participants With Worsening in Dental Status at Week 54

    Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 54 dental assessments versus baseline dental assessments.

    Time frame: Week 54

08

Results

Posted Dec 16, 2020

Participant flow

The study recruited participants in clinics/clinical offices in 42 countries.

Randomization
Participant flow — Randomization
MilestoneSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Started969095
Completed959095
Not completed1000
Withdrew: Not treated1000
Weeks 0-20
Participant flow — Weeks 0-20
MilestoneSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Started959095
Treated959095
Completed858685
Not completed10410
Withdrew: Lost to follow-up2000
Withdrew: Withdrawal by parent/guardian5200
Withdrew: Withdrawal by subject3210
Weeks 20-54
Participant flow — Weeks 20-54
MilestoneSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Started858685
Completed747865
Not completed11820
Withdrew: Lost to follow-up4310
Withdrew: Withdrawal by parent/guardian2210
Withdrew: Withdrawal by subject5300

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (A1C) at Week 20

Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C.

Time frame:
Baseline and Week 20
Reported as:
Mean · Percentage
Change From Baseline in Hemoglobin A1C (A1C) at Week 20
PercentageSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Hemoglobin A1C (A1C) at Week 20-0.13 ± 1.58-0.02 ± 1.45-1.03 ± 0.720.57 ± 1.62
PrimaryBaseline Glycated Hemoglobin (A1C) for the Placebo (Pooled) Arm

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.

Time frame:
Baseline
Reported as:
Mean · Percentage
Baseline Glycated Hemoglobin (A1C) for the Placebo (Pooled) Arm
PercentagePlacebo (Pooled)
Baseline Glycated Hemoglobin (A1C) for the Placebo (Pooled) Arm7.58 ± 1.06
PrimaryChange From Baseline In A1C at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))

Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline was estimated as the Week 20 A1C minus the Week 0 A1C from a longitudinal data analysis (LDA) model. The placebo arm in this comparison is a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The Statistical Analysis Plan (SAP) did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · Percentage
Change From Baseline In A1C at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))
PercentageSitagliptinPlacebo (Pooled)
Change From Baseline In A1C at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))-0.01 (-0.35 to 0.34)0.18 (-0.17 to 0.53)
Statistical analysis
  • Sitagliptin vs Placebo (Pooled) · Mixed Models Analysis · p = = 0.448 · Least squares means difference: -0.19 · 95% CI -0.68 to 0.30The Least Squares (LS) Mean for the arm "Sitagliptin" is compared against that of "Placebo (pooled)".
PrimaryNumber of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56

The number of participants experiencing ≥1 adverse event during Weeks 0-56 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to Week 56
Reported as:
Count of participants · Participants
Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56
ParticipantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56736774
PrimaryPercentage of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)

The number of participants experiencing ≥1 adverse event during Weeks 0-56 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

Time frame:
Up to Week 56
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)
Percentage of participantsSitagliptinPlacebo/Metformin
Percentage of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)76.874.4
Statistical analysis
  • Sitagliptin vs Placebo/Metformin · Difference in percentage: 2.4 · 95% CI -10.0 to 14.9
PrimaryNumber of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54

The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to Week 54
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54
ParticipantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Number of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-545100
PrimaryPercentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)

The percentage of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is any untoward medical occurrence in a person administered a pharmaceutical product and does not have to have a causal relationship with this treatment. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

Time frame:
Up to Week 54
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)
Percentage of participantsSitagliptinPlacebo/Metformin
Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin)5.31.1
Statistical analysis
  • Sitagliptin vs Placebo/Metformin · Difference in percentage: 4.2 · 95% CI -1.3 to 10.8
SecondaryChange From Baseline in A1C at Week 54

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. This change from baseline reflects the Week 54 A1C minus the Week 0 A1C.

Time frame:
Baseline and Week 54
Reported as:
Mean · Percentage
Change From Baseline in A1C at Week 54
PercentageSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in A1C at Week 54-0.19 ± 1.37-0.90 ± 1.41-0.70 ± 0.94-0.50 ± NA
SecondaryPercentage of Participants With A1C at Goal (<7.0%) at Week 20

The percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).

Time frame:
Week 20
Reported as:
Number · Percentage of Participants
Percentage of Participants With A1C at Goal (<7.0%) at Week 20
Percentage of ParticipantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percentage of Participants With A1C at Goal (<7.0%) at Week 2049.537.877.820.0
SecondaryPercentage of Participants With A1C at Goal (<7.0%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))

The percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

Time frame:
Week 20
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C at Goal (<7.0%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))
Percentage of participantsSitagliptinPlacebo (Pooled)
Percentage of Participants With A1C at Goal (<7.0%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))49.536.8
Statistical analysis
  • Sitagliptin vs Placebo (Pooled) · Miettinen and Nurminen · p = = 0.374 (Percentage of participants with an A1C goal (7.0%) in the arm "Sitagliptin" was compared against the arm "Placebo (pooled)".) · Difference in percentage: 6.7 · 95% CI -8.1 to 21.2
SecondaryPercentage of Participants With A1C at Goal (<6.5%) at Week 20

The percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).

Time frame:
Week 20
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C at Goal (<6.5%) at Week 20
Percentage of participantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percentage of Participants With A1C at Goal (<6.5%) at Week 2030.523.366.720.0
SecondaryPercentage of Participants With A1C at Goal (<6.5%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))

The percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented. The analysis table includes the observed values for each treatment arm (Missing = Not at Goal) and the estimated treatment difference (Missing = Multiple Imputation). The current outcome measure focused on comparing results from participants randomized to sitagliptin or placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

Time frame:
Week 20
Reported as:
Number · Percentage of Participants
Percentage of Participants With A1C at Goal (<6.5%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))
Percentage of ParticipantsSitagliptinPlacebo (Pooled)
Percentage of Participants With A1C at Goal (<6.5%) at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))30.523.2
Statistical analysis
  • Sitagliptin vs Placebo (Pooled) · Miettinen and Nurminen · p = = 0.639 · Difference in percentage: 3.6 · 95% CI -11.6 to 18.3The percentage of participants with an A1C at the A1C goal (6.5%) in the arm "Sitagliptin" was compared against the arm "Placebo (pooled)".
SecondaryPercentage of Participants With A1C at Goal (<7.0%) at Week 54

The percentage of participants with A1C at goal (\<7.0%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).

Time frame:
Week 54
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C at Goal (<7.0%) at Week 54
Percentage of participantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percentage of Participants With A1C at Goal (<7.0%) at Week 5428.440.033.320.0
SecondaryPercentage of Participants With A1C at Goal (<6.5%) at Week 54

The percentage of participants with A1C at goal (\<6.5%) at Week 54 was presented. All numbers shown in each individual treatment arm are based on the observed values (Missing = Not at Goal).

Time frame:
Week 54
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C at Goal (<6.5%) at Week 54
Percentage of participantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percentage of Participants With A1C at Goal (<6.5%) at Week 5420.035.622.220.0
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 20

Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline.

Time frame:
Baseline and Week 20
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20
mg/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 209.98 ± 61.867.59 ± 41.11-19.88 ± 49.7857.67 ± 51.05
SecondaryBaseline Fasting Plasma Glucose (FPG) for the Placebo (Pooled) Arm

Blood glucose was measured on a fasting basis. The Placebo (pooled) arm was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms for analysis purposes.

Time frame:
Baseline
Reported as:
Mean · mg/dL
Baseline Fasting Plasma Glucose (FPG) for the Placebo (Pooled) Arm
mg/dLPlacebo (Pooled)
Baseline Fasting Plasma Glucose (FPG) for the Placebo (Pooled) Arm138.8 ± 42.4
SecondaryChange From Baseline in FPG at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))

Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 20 minus FPG at baseline and was estimated from a longitudinal data analysis model. The current outcome measure focused on results from participants randomized to sitagliptin or placebo. The Week 20 treatment comparison of Sitagliptin vs Placebo included all participants treated with Sitagliptin or Placebo. The Placebo arm in this comparison was a pooling of the Placebo/Metformin and Placebo/Sitagliptin arms. The SAP did not specify for the Metformin arm to be included in statistical comparisons, so results for this arm are provided separately.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))
mg/dLSitagliptinPlacebo (Pooled)
Change From Baseline in FPG at Week 20 (Analysis of Selected Arms: Sitagliptin and Placebo (Pooled))7.2 (-4.2 to 18.7)5.7 (-6.0 to 17.4)
Statistical analysis
  • Sitagliptin vs Placebo (Pooled) · Mixed Models Analysis · p = = 0.849 · Least squares means difference: 1.5 · 95% CI -14.4 to 17.5The Least Squares (LS) Mean for the arm "Sitagliptin" was compared against that of "Placebo (pooled)".
SecondaryChange From Baseline in FPG at Week 54

Blood glucose was measured on a fasting basis. Change in plasma glucose levels was FPG at Week 54 minus FPG at baseline.

Time frame:
Baseline and Week 54
Reported as:
Mean · mg/dL
Change From Baseline in FPG at Week 54
mg/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in FPG at Week 54-3.03 ± 48.55-4.52 ± 50.68-29.92 ± 53.193.00 ± NA
SecondaryChange From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 20

PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour PMG minus the Week 0 2-hour PMG.

Time frame:
Baseline and Week 20
Reported as:
Mean · mg/dL
Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 20
mg/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 20-2.9 ± 42.62.1 ± 72.1-6.8 ± 21.163.5 ± 171.8
SecondaryChange From Baseline in 2-hour PMG at Week 54

PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour PMG minus the Week 0 2-hour PMG.

Time frame:
Baseline and Week 54
Reported as:
Mean · mg/dL
Change From Baseline in 2-hour PMG at Week 54
mg/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in 2-hour PMG at Week 54-1.7 ± 21.3-16.8 ± 48.9-39.7 ± 32.3-28.0 ± NA
SecondaryChange From Baseline in 2-hour Incremental PMG at Week 20

2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.

Time frame:
Baseline and Week 20
Reported as:
Mean · mg/dL
Change From Baseline in 2-hour Incremental PMG at Week 20
mg/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in 2-hour Incremental PMG at Week 201.5 ± 55.30.7 ± 35.90.8 ± 15.612.5 ± 98.3
SecondaryChange From Baseline in 2-Hour Incremental PMG at Week 54

2-Hour incremental PMG = Glucose at 120 minutes - glucose at 0 minutes. PMG endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 2-hour incremental PMG minus the Week 0 2-hour incremental PMG.

Time frame:
Baseline and Week 54
Reported as:
Mean · mg/dL
Change From Baseline in 2-Hour Incremental PMG at Week 54
mg/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in 2-Hour Incremental PMG at Week 54-0.6 ± 64.6-26.6 ± 39.0-31.3 ± 34.8-32.0 ± NA
SecondaryChange From Baseline in Insulin at Week 20 for Participants Not on Background Insulin

This change from baseline reflects the Week 20 insulin minus the Week 0 insulin.

Time frame:
Baseline and Week 20
Reported as:
Mean · mIU/L
Change From Baseline in Insulin at Week 20 for Participants Not on Background Insulin
mIU/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin at Week 20 for Participants Not on Background Insulin1.59 ± 47.24-3.91 ± 22.31-7.25 ± 60.58-1.23 ± 20.55
SecondaryChange From Baseline in Insulin at Week 54 For Participants Not on Background Insulin

This change from baseline reflects the Week 54 insulin minus the Week 0 insulin.

Time frame:
Baseline and Week 54
Reported as:
Mean · mIU/L
Change From Baseline in Insulin at Week 54 For Participants Not on Background Insulin
mIU/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin at Week 54 For Participants Not on Background Insulin-9.65 ± 40.82-6.64 ± 32.01-20.50 ± 65.08-9.95 ± NA
SecondaryChange From Baseline in Proinsulin at Week 20 For Participants Not on Background Insulin

This change from baseline reflects the Week 20 proinsulin minus the Week 0 proinsulin.

Time frame:
Baseline and Week 20
Reported as:
Mean · pmol/L
Change From Baseline in Proinsulin at Week 20 For Participants Not on Background Insulin
pmol/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Proinsulin at Week 20 For Participants Not on Background Insulin0.91 ± 81.88-10.88 ± 55.1212.57 ± 36.98-1.33 ± 9.07
SecondaryChange From Baseline in Proinsulin at Week 54 For Participants Not on Background Insulin

This change from baseline reflects the Week 54 proinsulin minus the Week 0 proinsulin.

Time frame:
Baseline and Week 54
Reported as:
Mean · pmol/L
Change From Baseline in Proinsulin at Week 54 For Participants Not on Background Insulin
pmol/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Proinsulin at Week 54 For Participants Not on Background Insulin-10.62 ± 67.54-16.13 ± 81.52-23.30 ± 42.36-0.50 ± NA
SecondaryChange From Baseline in Proinsulin/Insulin Ratio at Week 20 for Participants Not on Background Insulin

Change from baseline was the Week 20 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.

Time frame:
Baseline and Week 20
Reported as:
Mean · Ratio
Change From Baseline in Proinsulin/Insulin Ratio at Week 20 for Participants Not on Background Insulin
RatioSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Proinsulin/Insulin Ratio at Week 20 for Participants Not on Background Insulin0.02 ± 0.220.02 ± 0.16-0.03 ± 0.10-0.19 ± 0.45
SecondaryChange From Baseline in Proinsulin/Insulin Ratio at Week 54 For Participants Not on Background Insulin

The change from baseline was Week 54 proinsulin/insulin ratio minus the Week 0 proinsulin/insulin ratio.

Time frame:
Baseline and Week 54
Reported as:
Mean · Ratio
Change From Baseline in Proinsulin/Insulin Ratio at Week 54 For Participants Not on Background Insulin
RatioSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Proinsulin/Insulin Ratio at Week 54 For Participants Not on Background Insulin0.02 ± 0.23-0.03 ± 0.19-0.01 ± 0.060.02 ± NA
SecondaryChange From Baseline in Homeostatic Model Assessment of β-cell Function (HOMA-β) at Week 20 For Participants Not on Background Insulin

HOMA-β = 20 × fasting insulin (in mcIU/mL) ÷ {\[FPG (in mg/dL)/18\] - 3.5}. The change from baseline was Week 20 HOMA-β minus the Week 0 HOMA-β.

Time frame:
Baseline and Week 20
Reported as:
Mean · Percentage of Beta Cell Function
Change From Baseline in Homeostatic Model Assessment of β-cell Function (HOMA-β) at Week 20 For Participants Not on Background Insulin
Percentage of Beta Cell FunctionSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Homeostatic Model Assessment of β-cell Function (HOMA-β) at Week 20 For Participants Not on Background Insulin15.72 ± 162.47-53.23 ± 296.23-1757.50 ± 4765.46-64.78 ± 126.65
SecondaryChange From Baseline in HOMA-β at Week 54 For Participants Not on Background Insulin

HOMA-β = 20 × fasting insulin (in mcIU/mL) ÷ {\[FPG (in mg/dL)/18\] - 3.5}. This change from baseline was Week 54 HOMA-β minus the Week 0 HOMA-β.

Time frame:
Baseline and Week 54
Reported as:
Mean · Percentage of Beta Cell Function
Change From Baseline in HOMA-β at Week 54 For Participants Not on Background Insulin
Percentage of Beta Cell FunctionSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in HOMA-β at Week 54 For Participants Not on Background Insulin-41.15 ± 183.17-63.88 ± 339.74-1860.69 ± 4099.22-121.48 ± NA
SecondaryChange From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 20 For Participants Not on Background Insulin

HOMA-IR = fasting insulin (in mcIU/mL) × FPG (in mg/dL) / (22.5×18). This change from baseline was Week 20 HOMA-IR minus the Week 0 HOMA-IR.

Time frame:
Baseline and Week 20
Reported as:
Mean · Index of insulin resistance
Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 20 For Participants Not on Background Insulin
Index of insulin resistanceSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 20 For Participants Not on Background Insulin-0.50 ± 31.62-0.86 ± 9.02-4.46 ± 34.652.58 ± 9.30
SecondaryChange From Baseline in HOMA-IR at Week 54 For Participants Not on Background Insulin

HOMA-IR = fasting insulin (in mcIU/mL) × FPG (in mg/dL) / (22.5×18). This change from baseline was Week 54 HOMA-IR minus the Week 0 HOMA-IR.

Time frame:
Baseline and Week 54
Reported as:
Mean · Index of insulin resistance
Change From Baseline in HOMA-IR at Week 54 For Participants Not on Background Insulin
Index of insulin resistanceSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in HOMA-IR at Week 54 For Participants Not on Background Insulin-6.13 ± 34.86-1.30 ± 15.31-15.18 ± 36.41-2.21 ± NA
SecondaryChange From Baseline in Glucose 3-Hour Total Area Under the Curve (AUC) at Week 20

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.

Time frame:
Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · mg*hr/dL
Change From Baseline in Glucose 3-Hour Total Area Under the Curve (AUC) at Week 20
mg*hr/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Glucose 3-Hour Total Area Under the Curve (AUC) at Week 20-49.3 ± 103.62.0 ± 190.018.6 ± 50.9191.0 ± 434.2
SecondaryChange From Baseline in Insulin 3-hour AUC at Week 20

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.

Time frame:
Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · µIU*hr/mL
Change From Baseline in Insulin 3-hour AUC at Week 20
µIU*hr/mLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin 3-hour AUC at Week 20-14.5 ± 128.0-32.8 ± 99.9141.7 ± 206.1-145.6 ± 180.6
SecondaryChange From Baseline in C-peptide 3-Hour AUC at Week 20

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.

Time frame:
Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · ng*hr/mL
Change From Baseline in C-peptide 3-Hour AUC at Week 20
ng*hr/mLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in C-peptide 3-Hour AUC at Week 20-1.8 ± 4.9-0.1 ± 3.35.9 ± 7.6-6.4 ± 7.1
SecondaryChange From Baseline in Insulin 3-Hour AUC/ Glucose 3-Hour AUC Ratio at Week 20

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 20 insulin total AUC/glucose total AUC ratio minus the Week 0 insulin total AUC/glucose total AUC ratio.

Time frame:
Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · [µIU*hr/mL]/[mg*hr/dL]
Change From Baseline in Insulin 3-Hour AUC/ Glucose 3-Hour AUC Ratio at Week 20
[µIU*hr/mL]/[mg*hr/dL]SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin 3-Hour AUC/ Glucose 3-Hour AUC Ratio at Week 200.0 ± 0.3-0.1 ± 0.30.2 ± 0.4-0.2 ± 0.3
SecondaryChange From Baseline in Glucose Excursion 3-Hour AUC at Week 20

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.

Time frame:
Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · mg*hr/dL
Change From Baseline in Glucose Excursion 3-Hour AUC at Week 20
mg*hr/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Glucose Excursion 3-Hour AUC at Week 20-43.5 ± 97.410.8 ± 58.639.8 ± 50.146.2 ± 201.9
SecondaryChange From Baseline in Insulin Excursion 3-Hour AUC at Week 20

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.

Time frame:
Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · µIU*hr/mL
Change From Baseline in Insulin Excursion 3-Hour AUC at Week 20
µIU*hr/mLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin Excursion 3-Hour AUC at Week 20-12.4 ± 89.4-19.4 ± 93.687.5 ± 124.5-82.8 ± 93.4
SecondaryChange From Baseline in C-peptide Excursion 3-Hour AUC at Week 20

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.

Time frame:
Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · ng*hr/ml
Change From Baseline in C-peptide Excursion 3-Hour AUC at Week 20
ng*hr/mlSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in C-peptide Excursion 3-Hour AUC at Week 20-1.1 ± 3.1-0.4 ± 4.44.1 ± 5.6-4.8 ± 5.2
SecondaryChange From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 20

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 20 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.

Time frame:
Baseline and Week 20 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · [μIU*hr/mL]/[mg*hr/dL]
Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 20
[μIU*hr/mL]/[mg*hr/dL]SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 202.2 ± 9.67.2 ± 17.5-2.5 ± 3.21.4 ± 2.2
SecondaryChange From Baseline in Glucose 3-Hour AUC at Week 54

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 glucose 3-hour AUC minus the Week 0 glucose 3-hour AUC.

Time frame:
Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · mg*hr/dL
Change From Baseline in Glucose 3-Hour AUC at Week 54
mg*hr/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Glucose 3-Hour AUC at Week 54-21.1 ± 47.7-36.0 ± 136.1-73.1 ± 95.8-63.3 ± NA
SecondaryChange From Baseline in Insulin 3-Hour AUC at Week 54

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC minus the Week 0 insulin 3-hour AUC.

Time frame:
Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · µIU*hr/mL
Change From Baseline in Insulin 3-Hour AUC at Week 54
µIU*hr/mLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin 3-Hour AUC at Week 54-43.2 ± 259.8-253.9 ± 282.7-37.8 ± 9.4-184.4 ± NA
SecondaryChange From Baseline in C-peptide 3-Hour AUC at Week 54

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 C-peptide 3-hour AUC minus the Week 0 C-peptide 3-hour AUC.

Time frame:
Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · ng*hr/ml
Change From Baseline in C-peptide 3-Hour AUC at Week 54
ng*hr/mlSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in C-peptide 3-Hour AUC at Week 54-0.1 ± 5.7-6.1 ± 8.21.7 ± 1.0-8.9 ± NA
SecondaryChange From Baseline in Insulin 3-Hour AUC/Glucose 3-Hour AUC Ratio at Week 54

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. This change from baseline was Week 54 insulin 3-hour AUC/glucose 3-hour AUC ratio minus the Week 0 insulin 3-hour AUC/glucose 3-hour AUC ratio.

Time frame:
Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · [μIU*hr/mL]/[mg*hr/dL]
Change From Baseline in Insulin 3-Hour AUC/Glucose 3-Hour AUC Ratio at Week 54
[μIU*hr/mL]/[mg*hr/dL]SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin 3-Hour AUC/Glucose 3-Hour AUC Ratio at Week 54-0.1 ± 0.5-0.6 ± 0.8-0.0 ± 0.2-0.3 ± NA
SecondaryChange From Baseline in Glucose Excursion 3-Hour AUC at Week 54

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 glucose Excursion 3-hour AUC minus the Week 0 glucose Excursion 3-hour AUC.

Time frame:
Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · mg*hr/dL
Change From Baseline in Glucose Excursion 3-Hour AUC at Week 54
mg*hr/dLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Glucose Excursion 3-Hour AUC at Week 54-30.7 ± 100.7-50.1 ± 79.5-49.0 ± 87.5-74.0 ± NA
SecondaryChange From Baseline in Insulin Excursion 3-Hour AUC at Week 54

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC minus the Week 0 insulin Excursion 3-hour AUC.

Time frame:
Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · µIU*hr/mL
Change From Baseline in Insulin Excursion 3-Hour AUC at Week 54
µIU*hr/mLSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin Excursion 3-Hour AUC at Week 54-103.8 ± 151.0-198.5 ± 263.0-40.2 ± 11.5-116.6 ± NA
SecondaryChange From Baseline in C-Peptide Excursion 3-Hour AUC at Week 54

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 C-peptide Excursion 3-hour AUC minus the Week 0 C-peptide Excursion 3-hour AUC.

Time frame:
Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · ng*hr/ml
Change From Baseline in C-Peptide Excursion 3-Hour AUC at Week 54
ng*hr/mlSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in C-Peptide Excursion 3-Hour AUC at Week 54-1.8 ± 3.0-5.2 ± 8.80.9 ± 0.5-5.9 ± NA
SecondaryChange From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 54

AUC endpoints were derived via the trapezoidal rule using 9-point Meal Tolerance Test (MTT) measurements. Excursion AUC = Incremental AUC above the level at the start of the meal. AUC below the level at the start of the meal did not contribute to the Excursion AUC. This change from baseline was Week 54 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio minus the Week 0 insulin Excursion 3-hour AUC/glucose Excursion 3-hour AUC ratio.

Time frame:
Baseline and Week 54 (-10 min. before ingesting the meal, 0 min. prior to the meal, 10, 20, 30, 60, 90, 120, 180 minutes after ingesting the meal)
Reported as:
Mean · [µIU*hr/mL]/[mg*hr/dL]
Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 54
[µIU*hr/mL]/[mg*hr/dL]SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Insulin Excursion 3-Hour AUC/Glucose Excursion 3-Hour AUC Ratio at Week 544.1 ± 13.13.7 ± 5.6-2.7 ± 4.31.4 ± NA
SecondaryPercentage of Participants Initiating Glycemic Rescue Therapy by Week 20

The percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.

Time frame:
Up to Week 20
Reported as:
Number · Percentage of participants
Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20
Percentage of participantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percentage of Participants Initiating Glycemic Rescue Therapy by Week 205.311.10.040.0
SecondaryPercentage of Participants Initiating Glycemic Rescue Therapy by Week 54

The percentage of participants who initiated glycemic rescue therapy prior to Week 54 was reported.

Time frame:
Up to Week 54
Reported as:
Number · Percentage of participants
Percentage of Participants Initiating Glycemic Rescue Therapy by Week 54
Percentage of participantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percentage of Participants Initiating Glycemic Rescue Therapy by Week 5435.828.911.180.0
SecondaryChange From Baseline in Body Mass Index (BMI) at Week 20

This change from baseline was Week 20 BMI minus the Week 0 BMI.

Time frame:
Baseline and Week 20
Reported as:
Mean · kg/m^2
Change From Baseline in Body Mass Index (BMI) at Week 20
kg/m^2SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Body Mass Index (BMI) at Week 200.0 ± 2.2-0.7 ± 1.9-0.8 ± 1.4-1.7 ± 2.8
SecondaryChange From Baseline in BMI at Week 54

This change from baseline was Week 54 BMI minus the Week 0 BMI.

Time frame:
Baseline and Week 54
Reported as:
Mean · kg/m^2
Change From Baseline in BMI at Week 54
kg/m^2SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in BMI at Week 54-0.4 ± 2.9-1.0 ± 2.9-0.6 ± 1.3-0.3 ± 1.6
SecondaryMean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 20

The percent change from baseline in CD26 = (\[CD26 value at Week 20\] - \[baseline CD26 value\]) ÷ baseline CD26 value × 100.

Time frame:
Baseline and Week 20
Reported as:
Mean · Percent Change
Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 20
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 204.06 ± 19.25-1.78 ± 17.184.89 ± 1.9014.57 ± 15.46
SecondaryMean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 54

The percent change from baseline in CD26 = (\[CD26 value at Week 54\] - \[baseline CD26 value\]) ÷ baseline CD26 value × 100.

Time frame:
Baseline and Week 54
Reported as:
Mean · Percent Change
Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 54
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Mean Percent Change of Peripheral Blood Mononuclear Cells Expressing CD26 From Baseline at Week 544.74 ± 17.184.27 ± 18.2412.63 ± 13.02-5.30 ± 4.19
SecondaryChange From Baseline in Calcitonin at Week 20 - Females

Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.

Time frame:
Baseline and Week 20
Reported as:
Mean · ng/L
Change From Baseline in Calcitonin at Week 20 - Females
ng/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Calcitonin at Week 20 - Females-0.1 ± 0.5-2.0 ± 11.70.0 ± 0.00.0 ± 0.0
SecondaryChange From Baseline in Calcitonin at Week 54 - Females

Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.

Time frame:
Baseline and Week 54
Reported as:
Mean · ng/L
Change From Baseline in Calcitonin at Week 54 - Females
ng/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Calcitonin at Week 54 - Females-1.0 ± 0.6-1.9 ± 12.10.0 ± 0.00.3 ± 0.4
SecondaryChange From Baseline in Calcitonin at Week 20 - Males

Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 20 calcitonin minus the Week 0 calcitonin.

Time frame:
Baseline and Week 20
Reported as:
Mean · ng/L
Change From Baseline in Calcitonin at Week 20 - Males
ng/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Calcitonin at Week 20 - Males0.2 ± 1.4-0.2 ± 0.6-1.6 ± 2.20.5 ± 0.6
SecondaryChange From Baseline in Calcitonin at Week 54 - Males

Calcitonin, along with parathyroid hormone, is a hormone that regulates calcium and bone metabolism. This change from baseline was Week 54 calcitonin minus the Week 0 calcitonin.

Time frame:
Baseline and Week 54
Reported as:
Mean · ng/L
Change From Baseline in Calcitonin at Week 54 - Males
ng/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Calcitonin at Week 54 - Males0.1 ± 1.1-0.3 ± 0.90.0 ± NA1.4 ± 0.3
SecondaryChange From Baseline in Urine N-terminal Cross-linking Telopeptide of Bone Collagen [u-NTx]/Creatinine Ratio at Week 20 - Females

Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents

Time frame:
Baseline and Week 20
Reported as:
Mean · nmol(BCE)/mmol(creatinine)
Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Bone Collagen [u-NTx]/Creatinine Ratio at Week 20 - Females
nmol(BCE)/mmol(creatinine)SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Bone Collagen [u-NTx]/Creatinine Ratio at Week 20 - Females-28.7 ± 120.9-41.2 ± 148.9-98.0 ± 153.012.7 ± 29.2
SecondaryChange From Baseline u-NTx/Creatinine Ratio at Week 20 - Males

Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. BCE = Bone Collagen Equivalents

Time frame:
Baseline and Week 20
Reported as:
Mean · nmol(BCE)/mmol(creatinine)
Change From Baseline u-NTx/Creatinine Ratio at Week 20 - Males
nmol(BCE)/mmol(creatinine)SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline u-NTx/Creatinine Ratio at Week 20 - Males-30.9 ± 167.2-69.8 ± 162.162.0 ± NA-29.0 ± 32.5
SecondaryChange From Baseline in u-NTx/Creatinine Ratio at Week 54 - Females

Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. Bone Collagen Equivalents

Time frame:
Baseline and Week 54
Reported as:
Mean · nmol(BCE)/mmol(creatinine)
Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Females
nmol(BCE)/mmol(creatinine)SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Females-88.4 ± 102.6-61.2 ± 137.6-80.3 ± 208.5-17.0 ± 13.5
SecondaryChange From Baseline in u-NTx/Creatinine Ratio at Week 54 - Males

Urine N-terminal cross-linking telopeptide of bone collagen \[u-NTx\]/creatinine ratio is a biochemical marker of bone turnover/resorption. All participants in the Metformin arm were missing baseline or Week 54 measurements. BCE = Bone Collagen Equivalents

Time frame:
Baseline and Week 54
Reported as:
Mean · nmol(BCE)/mmol(creatinine)
Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Males
nmol(BCE)/mmol(creatinine)SitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in u-NTx/Creatinine Ratio at Week 54 - Males-78.2 ± 166.9-102.4 ± 267.7—-30.0 ± NA
SecondaryChange From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Females

Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.

Time frame:
Baseline and Week 20
Reported as:
Mean · μg/L
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Females
μg/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Females-6.0 ± 13.7-4.2 ± 9.9-9.7 ± 7.710.7 ± 9.7
SecondaryChange From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Females

Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.

Time frame:
Baseline and Week 54
Reported as:
Mean · μg/L
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Females
μg/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Females-20.0 ± 28.4-13.5 ± 18.1-14.9 ± 10.3-6.9 ± 9.2
SecondaryChange From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Males

Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 20 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.

Time frame:
Baseline and Week 20
Reported as:
Mean · μg/L
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Males
μg/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 20 - Males-2.2 ± 21.60.1 ± 19.9-7.1 ± 0.24.7 ± 8.2
SecondaryChange From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Males

Bone-specific alkaline phosphatase is a biochemical marker of bone turnover. This change from baseline was Week 54 bone-specific alkaline phosphatase minus the Week 0 bone-specific alkaline phosphatase.

Time frame:
Baseline and Week 54
Reported as:
Mean · μg/L
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Males
μg/LSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Bone-Specific Alkaline Phosphatase at Week 54 - Males-16.2 ± 28.0-15.0 ± 27.0-1.3 ± NA-15.3 ± 12.4
SecondaryPercent Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) at Week 20 - Females

IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 20\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.

Time frame:
Baseline and Week 20
Reported as:
Mean · Percent Change
Percent Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) at Week 20 - Females
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percent Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) at Week 20 - Females0.5 ± 21.911.0 ± 34.0-3.2 ± 14.941.4 ± 31.2
SecondaryPercent Change From Baseline in IGF-1 at Week 54 - Females

IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 54\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.

Time frame:
Baseline and Week 54
Reported as:
Mean · Percent Change
Percent Change From Baseline in IGF-1 at Week 54 - Females
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percent Change From Baseline in IGF-1 at Week 54 - Females-1.5 ± 34.47.2 ± 57.6-11.9 ± 13.4-13.5 ± NA
SecondaryPercent Change From Baseline in IGF-1 at Week 20 - Males

IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 20\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.

Time frame:
Baseline and Week 20
Reported as:
Mean · Percent Change
Percent Change From Baseline in IGF-1 at Week 20 - Males
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percent Change From Baseline in IGF-1 at Week 20 - Males-2.7 ± 22.19.3 ± 29.67.6 ± 17.45.3 ± 16.2
SecondaryPercent Change From Baseline in IGF-1 at Week 54 - Males

IGF-1 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-1 = (\[IGF-1 value at Week 54\] - \[baseline IGF-1 value\]) ÷ \[baseline IGF-1 value\] × 100.

Time frame:
Baseline and Week 54
Reported as:
Mean · Percent Change
Percent Change From Baseline in IGF-1 at Week 54 - Males
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percent Change From Baseline in IGF-1 at Week 54 - Males-4.9 ± 33.529.6 ± 99.818.8 ± NA-6.8 ± 22.1
SecondaryPercent Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) at Week 20 - Females

IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 20\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.

Time frame:
Baseline and Week 20
Reported as:
Mean · Percent Change
Percent Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) at Week 20 - Females
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percent Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) at Week 20 - Females3.5 ± 18.23.8 ± 13.88.4 ± 12.9-0.7 ± 24.1
SecondaryPercent Change From Baseline in IGF-BP3 at Week 54 - Females

IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 54\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.

Time frame:
Baseline and Week 54
Reported as:
Mean · Percent Change
Percent Change From Baseline in IGF-BP3 at Week 54 - Females
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percent Change From Baseline in IGF-BP3 at Week 54 - Females2.0 ± 16.74.5 ± 17.011.4 ± 17.4-13.4 ± 9.9
SecondaryPercent Change From Baseline in IGF-BP3 at Week 20 - Males

IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 20\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.

Time frame:
Baseline and Week 20
Reported as:
Mean · Percent Change
Percent Change From Baseline in IGF-BP3 at Week 20 - Males
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percent Change From Baseline in IGF-BP3 at Week 20 - Males5.6 ± 13.310.2 ± 18.63.3 ± 0.514.2 ± 50.6
SecondaryPercent Change From Baseline in IGF-BP3 at Week 54 - Males

IGF-BP3 is a biochemical marker of growth hormone action and growth. The percent change from baseline in IGF-BP3 = (\[IGF-BP3 value at Week 54\] - \[baseline IGF-BP3 value\]) ÷ \[baseline IGF-BP3 value\] × 100.

Time frame:
Baseline and Week 54
Reported as:
Mean · Percent Change
Percent Change From Baseline in IGF-BP3 at Week 54 - Males
Percent ChangeSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Percent Change From Baseline in IGF-BP3 at Week 54 - Males5.4 ± 18.418.2 ± 43.1-2.9 ± NA22.5 ± 8.3
SecondaryGrowth Velocity at Week 20 - Females

Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).

Time frame:
Week 20
Reported as:
Mean · cm/year
Growth Velocity at Week 20 - Females
cm/yearSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Growth Velocity at Week 20 - Females3.2 ± 8.21.9 ± 2.75.0 ± 6.80.6 ± 1.6
SecondaryGrowth Velocity at Week 54 - Females

Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).

Time frame:
Week 54
Reported as:
Mean · cm/year
Growth Velocity at Week 54 - Females
cm/yearSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Growth Velocity at Week 54 - Females2.1 ± 3.71.2 ± 1.82.4 ± 2.90.7 ± 1.0
SecondaryGrowth Velocity at Week 20 - Males

Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).

Time frame:
Week 20
Reported as:
Mean · cm/year
Growth Velocity at Week 20 - Males
cm/yearSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Growth Velocity at Week 20 - Males2.6 ± 2.73.6 ± 3.2-1.0 ± 1.31.7 ± 2.4
SecondaryGrowth Velocity at Week 54 - Males

Growth Velocity (cm/year) = (Change from Baseline in height)/(Change from Baseline in chronologic age).

Time frame:
Week 54
Reported as:
Mean · cm/year
Growth Velocity at Week 54 - Males
cm/yearSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Growth Velocity at Week 54 - Males2.5 ± 2.52.8 ± 2.11.7 ± NA2.8 ± 4.0
SecondarySkeletal Maturation at Week 20 - Females

Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from an X-ray of left hand and wrist.

Time frame:
Week 20
Reported as:
Mean · Ratio
Skeletal Maturation at Week 20 - Females
RatioSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Skeletal Maturation at Week 20 - Females0.6 ± 1.90.4 ± 1.81.7 ± 2.3-0.8 ± 5.5
SecondarySkeletal Maturation at Week 54 - Females

Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Placebo/Sitagliptin arm were missing baseline or Week 54 measurements.

Time frame:
Week 54
Reported as:
Mean · Ratio
Skeletal Maturation at Week 54 - Females
RatioSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Skeletal Maturation at Week 54 - Females1.3 ± 1.11.0 ± 0.61.3 ± 2.2—
SecondarySkeletal Maturation at Week 20 - Males

Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist.

Time frame:
Week 20
Reported as:
Mean · Ratio
Skeletal Maturation at Week 20 - Males
RatioSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Skeletal Maturation at Week 20 - Males1.6 ± 1.71.2 ± 1.10.4 ± NA2.4 ± NA
SecondarySkeletal Maturation at Week 54 - Males

Skeletal Maturation = (Change from Baseline in bone age)/(Change from Baseline in chronologic age). Bone age was determined from X-ray of left hand and wrist. All participants in the Metformin and Placebo/Sitagliptin arms were missing baseline or Week 54 measurements.

Time frame:
Week 54
Reported as:
Mean · Ratio
Skeletal Maturation at Week 54 - Males
RatioSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Skeletal Maturation at Week 54 - Males1.3 ± 0.91.3 ± 0.6——
SecondaryChange From Baseline in Tanner Staging for Genitalia at Week 20 - Males

Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 20 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia.

Time frame:
Baseline and Week 20
Reported as:
Mean · Score on a scale
Change From Baseline in Tanner Staging for Genitalia at Week 20 - Males
Score on a scaleSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Tanner Staging for Genitalia at Week 20 - Males0.3 ± 0.50.2 ± 0.40.0 ± NA0.5 ± 0.7
SecondaryChange From Baseline in Tanner Staging for Genitalia at Week 54 - Males

Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of genital development (males) with a score of range 1 to 5 where 1=no development and 5=adult genitals. This change from baseline was Week 54 Tanner Staging for Genitalia minus the Week 0 Tanner Staging for Genitalia. All participants in the Metformin arm were missing baseline or Week 54 measurements.

Time frame:
Baseline and Week 54
Reported as:
Mean · Score on a scale
Change From Baseline in Tanner Staging for Genitalia at Week 54 - Males
Score on a scaleSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Tanner Staging for Genitalia at Week 54 - Males0.5 ± 0.60.6 ± 0.7—0.6 ± 0.7
SecondaryChange From Baseline in Tanner Staging for Breasts at Week 20 - Females

Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 20 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.

Time frame:
Baseline and Week 20
Reported as:
Mean · Score on a Scale
Change From Baseline in Tanner Staging for Breasts at Week 20 - Females
Score on a ScaleSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Tanner Staging for Breasts at Week 20 - Females0.2 ± 0.60.1 ± 0.30.2 ± 0.40.3 ± 0.6
SecondaryChange From Baseline in Tanner Staging for Breasts at Week 54 - Females

Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of breast development (females). Tanner stage (breast) is a score of range 1 to 5 where 1=no development and 5=adult breast. This change from baseline was Week 54 Tanner Staging for Breasts minus the Week 0 Tanner Staging for Breasts.

Time frame:
Baseline and Week 54
Reported as:
Mean · Score on a Scale
Change From Baseline in Tanner Staging for Breasts at Week 54 - Females
Score on a ScaleSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Tanner Staging for Breasts at Week 54 - Females0.5 ± 0.70.4 ± 0.60.5 ± 1.00.7 ± 0.6
SecondaryChange From Baseline in Tanner Stage for Pubic Hair at Week 20 - Females

Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.

Time frame:
Baseline and Week 20
Reported as:
Mean · Score on a scale
Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Females
Score on a scaleSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Females0.1 ± 0.40.1 ± 0.30.2 ± 0.40.0 ± 0.0
SecondaryChange From Baseline in Tanner Stage for Pubic Hair at Week 54 - Females

Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in female participants. Tanner staging includes an assessment of pubic hair development (females). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.

Time frame:
Baseline and Week 54
Reported as:
Mean · Score on a scale
Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Females
Score on a scaleSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Females0.5 ± 0.60.3 ± 0.50.8 ± 1.50.3 ± 0.6
SecondaryChange From Baseline in Tanner Stage for Pubic Hair at Week 20 - Males

Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 20 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.

Time frame:
Baseline and Week 20
Reported as:
Mean · Score on a scale
Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Males
Score on a scaleSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Tanner Stage for Pubic Hair at Week 20 - Males0.3 ± 0.50.2 ± 0.40.0 ± NA0.5 ± 0.7
SecondaryChange From Baseline in Tanner Stage for Pubic Hair at Week 54 - Males

Participant's stage of sexual maturation was assessed using the Tanner staging measure for determining pubertal development in male participants. Tanner staging includes an assessment of pubic hair development (males). Tanner stage (pubic hair) is a score of range 1 to 5 where 1=no development and 5=adult pubic hair. This change from baseline was Week 54 Tanner Staging for Pubic Hair minus the Week 0 Tanner Staging for Pubic Hair.

Time frame:
Baseline and Week 54
Reported as:
Mean · Score on a scale
Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Males
Score on a scaleSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Change From Baseline in Tanner Stage for Pubic Hair at Week 54 - Males0.5 ± 0.70.6 ± 0.5—0.5 ± 0.7
SecondaryParticipants With Worsening in Dental Status at Week 20

Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 20 dental assessments versus baseline dental assessments.

Time frame:
Week 20
Reported as:
Count of participants · Participants
Participants With Worsening in Dental Status at Week 20
ParticipantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
1. With ≥1 tooth with worsening in any category322510
2. With ≥1 tooth with worsening fracture5500
3. With ≥1 tooth with worsening discoloration292300
4. With ≥1 tooth with worsening enamel defect7410
SecondaryParticipants With Worsening in Dental Status at Week 54

Participants were evaluated with a visual oral exam; a subset had dental photographs. Teeth worsening was defined as worsening of tooth fracture, tooth discoloration, or enamel defect as determined by an independent reviewer. Worsening in these categories was a change in dental defect assessments made by comparing Week 54 dental assessments versus baseline dental assessments.

Time frame:
Week 54
Reported as:
Count of participants · Participants
Participants With Worsening in Dental Status at Week 54
ParticipantsSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
1. With ≥1 tooth with worsening in any category495020
2. With ≥1 tooth with worsening fracture131510
3. With ≥1 tooth with worsening discoloration454820
4. With ≥1 with worsening enamel defect131310

Adverse events

Collected over SAEs and AEs: Up to approximately Week 56. Deaths: Up to approximately 42 months after randomization.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin1/96 (1%)10/95 (10.5%)62/95 (65.3%)
Placebo/Metformin0/90 (0%)7/90 (7.8%)53/90 (58.9%)
Metformin0/9 (0%)1/9 (11.1%)7/9 (77.8%)
Placebo/Sitagliptin0/5 (0%)3/5 (60%)4/5 (80%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
Blood glucose increasedInvestigations1/950/900/91/5
Affect labilityPsychiatric disorders0/950/900/91/5
NephrolithiasisRenal and urinary disorders0/950/900/91/5
AppendicitisInfections and infestations0/951/901/90/5
HyperglycaemiaMetabolism and nutrition disorders3/950/900/90/5
Dengue feverInfections and infestations0/951/900/90/5
Gastroenteritis viralInfections and infestations0/951/900/90/5
ConcussionInjury, poisoning and procedural complications0/951/900/90/5
DehydrationMetabolism and nutrition disorders0/951/900/90/5
Diabetic ketoacidosisMetabolism and nutrition disorders0/951/900/90/5
Most frequent other events
Showing 10 of 38
Most frequent other events
EventSitagliptinPlacebo/MetforminMetforminPlacebo/Sitagliptin
HypoglycaemiaMetabolism and nutrition disorders16/9512/903/92/5
DizzinessNervous system disorders3/952/900/92/5
DiarrhoeaGastrointestinal disorders8/9511/902/90/5
HeadacheNervous system disorders9/9513/902/91/5
Eye painEye disorders0/950/900/91/5
PertussisInfections and infestations0/950/900/91/5
Upper respiratory tract infectionInfections and infestations12/9512/901/91/5
Viral infectionInfections and infestations0/950/900/91/5
Alanine aminotransferase increasedInvestigations4/953/900/91/5
Pain in extremityMusculoskeletal and connective tissue disorders1/951/901/91/5

Baseline characteristics

The analysis population consisted of all randomized and treated participants.

Age, Continuous
Age, Continuous(years)SitagliptinPlacebo/MetforminMetforminPlacebo/SitagliptinTotal
Mean14.3 ± 2.013.7 ± 1.913.3 ± 3.015.0 ± 1.614.0 ± 2.0
Age, Customized
Age, Customized(Participants)SitagliptinPlacebo/MetforminMetforminPlacebo/SitagliptinTotal
In utero00000
Preterm newborn infants (gestational age < 37 wks)00000
Newborns (0-27 days)00000
Infants and toddlers (28 days-23 months)00000
Children (2-11 years)11113025
Adolescents (12-17 years)847965174
Adults (18-64 years)00000
From 65-84 years00000
85 years and over00000
Unknown00000
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlacebo/MetforminMetforminPlacebo/SitagliptinTotal
Female545863121
Male41323278
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SitagliptinPlacebo/MetforminMetforminPlacebo/SitagliptinTotal
Hispanic or Latino36332273
Not Hispanic or Latino535453115
Unknown or Not Reported632011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SitagliptinPlacebo/MetforminMetforminPlacebo/SitagliptinTotal
American Indian or Alaska Native690015
Asian13141230
Native Hawaiian or Other Pacific Islander00000
Black or African American821011
White484763104
More than one race20181039
Unknown or Not Reported00000
Glycated Hemoglobin (A1C)
Glycated Hemoglobin (A1C)(Percentage)SitagliptinPlacebo/MetforminMetforminPlacebo/SitagliptinTotal
Mean7.43 ± 1.027.56 ± 1.087.43 ± 1.078.02 ± 0.757.50 ± 1.04
Fasting Plasma Glucose
Fasting Plasma Glucose(mg/dL)SitagliptinPlacebo/MetforminMetforminPlacebo/SitagliptinTotal
Mean138.4 ± 47.2138.6 ± 42.8134.6 ± 59.1142.2 ± 38.7138.6 ± 44.7
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Shankar RR, Zeitler P, Deeb A, Jalaludin MY, Garcia R, Newfield RS, Samoilova Y, Rosario CA, Shehadeh N, Saha CK, Zhang Y, Zilli M, Scherer LW, Lam RLH, Golm GT, Engel SS, Kaufman KD. A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Pediatr Diabetes. 2022 Mar;23(2):173-182. doi: 10.1111/pedi.13279. Epub 2021 Dec 22. PubMed 34779087 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Oct 2019, 91 months.

Results were first posted in Dec 2020, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 91 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2011
First posted
Dec 5, 2011
StartActual
Feb 10, 2012
Primary completionActual
Oct 9, 2019
CompletionActual
Oct 9, 2019
Results first posted
Dec 16, 2020
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01485614
Responsible party
Sponsor
First posted
Dec 5, 2011
Start date
Feb 10, 2012
Primary completion
Oct 9, 2019
Completion
Oct 9, 2019
Results posted
Dec 16, 2020
Last update
Sep 23, 2022

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion